Diversified Trust Co Has $1.36 Million Stake in Bio-Rad Laboratories, Inc. $BIO

Diversified Trust Co lowered its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 39.8% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,897 shares of the medical research company’s stock after selling 3,237 shares during the period. Diversified Trust Co’s holdings in Bio-Rad Laboratories were worth $1,365,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Danske Bank A S bought a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth about $30,000. Geneos Wealth Management Inc. increased its stake in shares of Bio-Rad Laboratories by 115.2% in the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares during the period. Los Angeles Capital Management LLC bought a new position in Bio-Rad Laboratories in the 4th quarter valued at approximately $47,000. Farther Finance Advisors LLC boosted its position in Bio-Rad Laboratories by 76.9% during the 4th quarter. Farther Finance Advisors LLC now owns 184 shares of the medical research company’s stock worth $56,000 after buying an additional 80 shares during the period. Finally, Itau Unibanco Holding S.A. boosted its position in Bio-Rad Laboratories by 57.6% during the 4th quarter. Itau Unibanco Holding S.A. now owns 197 shares of the medical research company’s stock worth $60,000 after buying an additional 72 shares during the period. Institutional investors and hedge funds own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Down 0.5%

Shares of NYSE BIO opened at $280.92 on Tuesday. The company’s 50 day moving average price is $284.62 and its 200-day moving average price is $289.24. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.37 and a current ratio of 3.21. Bio-Rad Laboratories, Inc. has a 52-week low of $228.40 and a 52-week high of $343.12. The company has a market capitalization of $7.52 billion, a P/E ratio of 46.28 and a beta of 1.08.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $1.89 earnings per share for the quarter, missing the consensus estimate of $1.97 by ($0.08). Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.The firm had revenue of $592.10 million for the quarter, compared to analyst estimates of $589.91 million. During the same quarter last year, the company earned $2.54 earnings per share. The company’s quarterly revenue was up 1.1% compared to the same quarter last year. Equities analysts forecast that Bio-Rad Laboratories, Inc. will post 9.42 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on BIO. Royal Bank Of Canada began coverage on shares of Bio-Rad Laboratories in a report on Friday, May 15th. They set an “outperform” rating and a $320.00 target price on the stock. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and dropped their price target for the company from $375.00 to $300.00 in a research note on Tuesday, April 7th. Wells Fargo & Company cut their price target on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a report on Friday, May 1st. Finally, Weiss Ratings cut shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $303.33.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.